Heat boosts radiation in prostate cancer comeback trial
NCT ID NCT02899221
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tested a combination of heat therapy (hyperthermia) and high-dose radiation for men whose prostate cancer returned after earlier radiation. Only 3 men took part, and the main goal was to check safety and side effects. The approach aims to make cancer cells more sensitive to radiation by heating them.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
3 people
The number who actually took part.
- Started
-
Mar 2017
- Finished
-
Oct 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Male participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Male age \>= 18 years * Karnofsky performance status \> 70% * Expected survival of at least 3 years * Informed consent signed by the subject * PSA blood test within 60 days prior to registration * Prostate biopsy with Gleason score and TNM staging within one year prior to registration * No evidence of metastasis on computed tomography (CT) or magnetic resonance imaging (MRI) of the pelvis within 120 days prior to registration * No evidence of metastasis on bone scan within 120 days prior to registration * Within 60 days prior to registration, hematologic minimal values: absolute neutrophil count \> 1,500/mm\^3 * Within 60 days prior to registration, hematologic minimal values: hemoglobin \> 8.0 g/dl * Within 60 days prior to registration, hematologic minimal values: platelet count \> 100,000/mm\^3 * Men of childbearing potential must be willing to consent to using effective contraception while on treatment and for at least 3 months after completion of treatment * Histologically proven persistent or recurrent adenocarcinoma of the prostate following prior external beam radiation therapy or brachytherapy * Prior androgen deprivation or chemotherapy is allowed if discontinued at least 30 days prior to enrollment * Concurrent disease - patients under treatment for concurrent medical conditions will be eligible for protocol treatment if, in the opinion of the physician responsible for hyperthermia treatment that the concurrent medical condition will neither interfere with the process of the treatment or patient assessments nor add significantly to the risks or complications of the treatment Exclusion Criteria: * History of urological surgery or procedures predisposing to genitourinary (GU) complications after radiation, i.e., anastomoses, stricture repair, transurethral resection, etc. (will be determined by radiation oncologist) * Prior thermal ablative therapy for prostate cancer (e.g. high-intensity focused ultrasound \[HIFU\] or cryoablation) * Documented distant metastatic disease * Patient with other co-morbidities that in the opinion of the treating physician would be a contra-indication to protocol participation (e.g. inflammatory bowel disease) * Mental incompetence or criminal incarceration
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Recurrent prostate carcinoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sidney Kimmel Cancer Center at Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New PET tracer could reveal hidden prostate cancer
- Intermittent fasting tested to ease radiation side effects in cancer patients
- New scan could sharpen radiation targeting for recurrent prostate cancer
- Old drug, new hope: niclosamide combo tackles tough prostate cancer
- New radiation approach targets multiple tumors at once in early trial
- New imaging agent could help surgeons find hidden prostate cancer